Subject: Medarex Share Offering To Develop Bioproducts
Date: Published: 7/30/92 (23 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Financing Business:
    Medarex Inc. 
 ESTIMATED INFORMATION UNITS:  1.4     WORDS:  100

    MEDAREX Inc., Princeton, N. J., said it plans a one-million-share
 public offering to raise funds for clinical trials and continuing
 product development.  The biopharmaceutical company, which is
 developing drugs to treat cancer, AIDS and infectious and autoimmune
 diseases based on monoclonal antibodies, said no current
 shareholders are selling in the offering.  It indicated the plan in a
 filing with the Securities and Exchange Commission.  A spokesman said
 the offering is expected by the end of August.  Underwriters are
 Josephthal Lyon & Ross Associates Inc. and Nomura Securities
 International Inc. Medarex shares closed yesterday at $8.50, up 12.5
 cents, in over-the-counter trading.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]